RM 006
Alternative Names: RM-006; RMC 6272Latest Information Update: 24 May 2023
At a glance
- Originator REVOLUTION Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action MTORC1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 21 Apr 2021 Revolution Medicines has patent protection for RMC 006 in USA